Functional Cure and Novel Therapeutics in Chronic Hepatitis B
Nov
2026
Description
This session reviews progress toward functional cure in chronic hepatitis B, featuring phase 2/3 data on bepirovirsen, siRNA therapy, and immune correlates of HBsAg decline.
Presentations
11:00 AM
- 11:15 AM
Convention Center - Bluebird Ballroom 1C
Rates of functional cure in participants with chronic hepatitis B virus (HBV) infection treated with bepirovirsen: B-Well Phase 3 trials end of study results
Man-Fung MF Yuen, MD, PhD, DSc | Abstract Presenter
11:15 AM
- 11:30 AM
Convention Center - Bluebird Ballroom 1C
Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon hepatitis B surface antigen at Week 12
Pietro Lampertico, MD, PhD | Abstract Presenter
11:30 AM
- 11:45 AM
Convention Center - Bluebird Ballroom 1C
Single-cell transcriptional landscape of HBV in chronic hepatitis B infection uncovers lower cccDNA transcription during treatment and in HBeAg-negative infection
Prakriti Sinha, PhD | Abstract Presenter
11:45 AM
- 12:00 PM
Convention Center - Bluebird Ballroom 1C
Paired Liver Biopsy Analysis of HBV Integration During Five Years of Nucleos(t)ide Analogue Therapy: Declining Evidence Burden and Delayed HBV DNA Suppression
Sujun Zheng | Abstract Presenter
12:00 PM
- 12:15 PM
Convention Center - Bluebird Ballroom 1C
Monotherapy with siRNA HRS-5635 induces an HBsAg loss in chronic HBV infection: a multicenter, randomized, phase II study
Jinlin Hou, MD | Abstract Presenter
12:15 PM
- 12:30 PM
Convention Center - Bluebird Ballroom 1C
Immune remodeling after HBV functional cure features coordinated enrichment of GZMK⁺ CD8⁺ T cells and activated memory B cells
Qi Zheng | Abstract Presenter
